Europe Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group

List of Tables

The influenza vaccines market in Europe is expected to grow from US$ 2,261.85 million in 2022 to US$ 3,424.02 million by 2028; it is estimated to grow at a CAGR of 7.2% from 2022 to 2028.

Increasing Investment by Top Market Players and Governments Boosts Europe Influenza Vaccines Market

Market players and governments worldwide are increasing their investments in vaccine development and immunization. For instance, in March 2021, Sanofi (Paris, France) announced an approximately US$ 925 million investment in a new vaccine manufacturing plant at its pre-existing site in Toronto, Canada. Investments in the new facility will provide additional antigen and filling capacity for Sanofi's FLUZONE high-dose quadrivalent influenza vaccines, increasing availability in Canada, the US, and Europe in the coming years. In April 2021, 3 levels of government-federal, provincial, and municipal-supported Sanofi Pasteur in building an "end-to-end" influenza vaccines factory in Toronto. The partners will invest ~US$ 1 billion to get the site up and running by 2027. Sanofi, for its part, will invest more than US$ 55 million, create 165 new eligible jobs, and maintain another 1,100. In addition, Sanofi will also invest ~US$ 79 million annually for 8 years to fund research and development in Canada.

In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories across the world. In April 2022, the bank provided a US$ 15.27 million loan to IRBM, an Italian biomedical research company, to expand its vaccine production capacity and strengthen research on COVID-19 and other diseases. Thus, the increase in investment by top market players and governments across the region is bolstering the Europe influenza vaccines market.

Market Overview

Europe accounted for the second largest market owing to factors such as the rising geriatric population, increasing prevalence of flu and related illness, and growing demand for the development of new vaccines in the region. In addition, growing funding for research & development activities is likely to provide more opportunities in the coming years across the region.

Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Europe Influenza Vaccines Market Segmentation

The Europe influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the Europe influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the Europe influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the Europe influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the Europe influenza vaccines market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Europe.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00026929

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Europe Influenza Vaccines Market - By Vaccine Type
- 1.3.2 Europe Influenza Vaccines Market - By Virus Type
- 1.3.3 Europe Influenza Vaccines Market - By Technology
- 1.3.4 Europe Influenza Vaccines Market - By Route of Administration
- 1.3.5 Europe Influenza Vaccines Market - By Target Group
- 1.3.6 Europe Influenza Vaccines Market - By Country

2. Europe Influenza Vaccines Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Influenza Vaccines Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Europe PEST Analysis
4.3 Experts Opinion

5. Europe Influenza Vaccines Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Government Support to Promote Influenza Vaccination
- 5.1.2 Increasing Investment by Top Market Players and Governments
5.2 Market Restraints
- 5.2.1 High Cost of Vaccine Development
5.3 Market Opportunities
- 5.3.1 Emerging Economies
5.4 Future Trends
- 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
5.5 Impact Analysis

6. Influenza Vaccine Market -Europe Analysis

6.1 Europe Influenza Vaccines Market, By Country - Forecasts And Analysis
6.2 Europe Influenza Vaccines Market Revenue Forecasts And Analysis
- 6.2.1 Europe: Influenza Vaccines Market, 2019-2028 (US$ Million)

7. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Vaccine Type

7.1 Overview
7.2 Europe Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
- 7.2.1 Europe: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
7.3 Quadrivalent Vaccines
- 7.3.1 Overview
- 7.3.2 Quadrivalent Vaccines : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Trivalent Vaccines
- 7.4.1 Overview
- 7.4.2 Trivalent Vaccines : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

8. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Virus Type

8.1 Overview
8.2 Europe Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
- 8.2.1 Europe: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
8.3 Influenza Virus Type A
- 8.3.1 Overview
- 8.3.2 Influenza Virus Type A : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Influenza Virus Type B
- 8.4.1 Overview
- 8.4.2 Influenza Virus Type B : Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

9. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Technology

9.1 Overview
9.2 Europe Influenza Vaccines Market, By Technology 2022 & 2028 (%)
- 9.2.1 Europe: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
9.3 Egg-based
- 9.3.1 Overview
- 9.3.2 Egg-based : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Cell-based
- 9.4.1 Overview
- 9.4.2 Cell-Based : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

10. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Route of Administration

10.1 Overview
10.2 Europe Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
- 10.2.1 Europe: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
- 10.2.2 Europe: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
10.3 Injection
- 10.3.1 Overview
- 10.3.2 Injection : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Nasal Spray
- 10.4.1 Overview
- 10.4.2 Nasal Spray: Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

11. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Target Group

11.1 Overview
11.2 Europe Influenza Vaccines Market, By Target Group 2022 & 2028 (%)
- 11.2.1 Europe: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
11.3 Infants
- 11.3.1 Overview
- 11.3.2 Infants : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Children
- 11.4.1 Overview
- 11.4.2 Children: Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Adults
- 11.5.1 Overview
- 11.5.2 Adults : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11.6 Elderly People
- 11.6.1 Overview
- 11.6.2 Elderly People: Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

12. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - Country Analysis

12.1 Europe: Influenza Vaccines Market
- 12.1.1 Overview
- 12.1.2 Europe: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
  - 12.1.2.1 Germany: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.1.1 Overview
    - 12.1.2.1.2 Germany: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.1.3 Germany: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.1.4 Germany: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.1.5 Germany: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.1.6 Germany: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.1.7 Germany: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.2 UK: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.2.1 Overview
    - 12.1.2.2.2 UK: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.2.3 UK: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.2.4 UK: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.2.5 UK: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.2.6 UK: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.2.7 UK: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.3 France: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.3.1 Overview
    - 12.1.2.3.2 France: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.3.3 France: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.3.4 France: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.3.5 France: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.3.6 France: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.3.7 France: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.4 Italy: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.4.1 Overview
    - 12.1.2.4.2 Italy: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.4.3 Italy: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.4.4 Italy: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.4.5 Italy: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.4.6 Italy: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.4.7 Italy: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.5 Spain: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.5.1 Overview
    - 12.1.2.5.2 Spain: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.5.3 Spain: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.5.4 Spain: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.5.5 Spain: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.5.6 Spain: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.5.7 Spain: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.6 Rest of Europe: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.6.1 Overview
    - 12.1.2.6.2 Rest of Europe: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.6.3 Rest of Europe: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.6.4 Rest of Europe: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.6.5 Rest of Europe: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.6.6 Rest of Europe: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.6.7 Rest of Europe: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)

13. Europe Influenza Vaccine Market -Industry Landscape

13.1 Overview
13.2 Growth Strategies in the Influenza Vaccine Market, 2021-2028
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Moderna, Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 SEQIRUS
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 GlaxoSmithKline plc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Emergent BioSolutions Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Mitsubishi Chemical Group Corporation
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Serum Institute of India Pvt. Ltd
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 MYLAN N.V.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 AstraZeneca
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms